Loading...

Brilliant Violet 421™ anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2_BV421_1_032911
C57BL/6 mouse splenocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), stained with CD3 FITC, fixed, permeabilized, and then stained with IFN-γ (clone XMG1.2) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • XMG1.2_BV421_1_032911
    C57BL/6 mouse splenocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), stained with CD3 FITC, fixed, permeabilized, and then stained with IFN-γ (clone XMG1.2) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • XMG1.2_BV421_2_032911
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
505829 125 µL £136
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505830 50 µg £166
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.1 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  2. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  3. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  4. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  5. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  6. Kim E, et al. 2022. Immunity. 55:145. PubMed
  7. Su C, et al. 2022. NPJ Vaccines. 7:168. PubMed
  8. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  9. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  10. Xu R 2023. Cell Reports. 42(2):112054. PubMed
  11. Ninnemann J, et al. 2022. Mucosal Immunol. 15:698. PubMed
  12. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  13. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  14. Rabia E, et al. 2023. Front Immunol. 14:1168444. PubMed
  15. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  16. Page N, et al. 2018. Immunity. 48:937. PubMed
  17. Weulersse M, et al. 2020. Immunity. 53(4):824-839.e10. PubMed
  18. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  19. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  20. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  21. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  22. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  23. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  24. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  25. Wang W, et al. 2020. Br J Pharmacol. 177:5569. PubMed
  26. Runge EM, et al. 2020. J Neuroinflammation. 17:121. PubMed
  27. Perrot I et al. 2019. Cell Rep. 27(8):2411-2425 . PubMed
  28. Gajdasik DW, et al. 2020. Nat Commun. 2.834027778. PubMed
  29. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  30. Rao TN, et al. 2020. J Immunol. 204:2600. PubMed
  31. van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
  32. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  33. Bunn P, et al. 2014. J Immunol. 192:3709. PubMed
  34. Lian J, et al. 2020. Cell Reports. 31(8):107679. PubMed
  35. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  36. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  37. Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
  38. Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed
  39. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  40. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
  41. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  42. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  43. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  44. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  45. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  46. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  47. Yang E, et al. 2016. J Immunol. 197: 934 - 941. PubMed
  48. Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed
  49. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  50. Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed
  51. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  52. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  53. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  54. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  55. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  56. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  57. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  58. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  59. Deng J, et al. 2021. EBioMedicine. 70:103505. PubMed
  60. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  61. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  62. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  63. Luo Z, et al. 2021. Int J Mol Sci. 22:. PubMed
  64. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  65. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  66. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  67. Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed
  68. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_10897937 (BioLegend Cat. No. 505829)
AB_10897937 (BioLegend Cat. No. 505830)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
IFN-gamma
Specificity Alt (DOES NOT SHOW ON TDS):
IFN-γ
App Abbreviation (DOES NOT SHOW ON TDS):
ICFC
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account